Hosted on MSN1mon
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pactOzempic weight-loss drug maker Novo Nordisk on Wednesday expanded an existing agreement with a drug developer that uses artificial intelligence. Novo Nordisk said an agreement reached last year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback